A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare hemoglobin response rates between two PROCRIT
(epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving
chemotherapy
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.